Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 11/20 | 0.52 |
| ▸ | PPARG | P37231 | 8/20 | 0.52 |
| ▸ | PPARD | Q03181 | 3/20 | 0.38 |
| ▸ | PTGES | O14684 | 2/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6832494 | 0.84 | CA12 (0.41) | PPARAPPARGCA12CA1CA2 | |
| SCHEMBL7858920 | 0.83 | PPARA (0.53) | PPARAPPARGPPARDCA12CA1 | |
| SCHEMBL7069550 | 0.83 | CA12 (0.40) | PPARAPPARGCA12CA1CA2 | |
| SCHEMBL4797598 | 0.82 | CA12 (0.40) | PPARAPPARGCA12CA1CA2 | |
| SCHEMBL6566136 | 0.80 | ACHE (0.38) | PPARAPPARGL3MBTL1 | |
| SCHEMBL3901614 | 0.75 | PPARA (0.50) | PPARAPPARGPPARDCA12CA1 | |
| SCHEMBL15558253 | 0.75 | L3MBTL1 (0.46) | L3MBTL1ALDH1A1 | |
| SCHEMBL6834536 | 0.74 | STS (0.39) | PPARAPPARGCA12CA1CA2 | |
| SCHEMBL6557772 | 0.74 | KDM4E (0.43) | TDP1CYP1A2L3MBTL1ALDH1A1 | |
| SCHEMBL7115003 | 0.74 | CA12 (0.38) | PPARAPPARGCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1528917-B1 | DOSAGE FORM COMPRISING HIGH DOSE HIGH SOLUBLE ACTIVE INGREDIENT AS MODIFIED RELEASE AND LOW DOSE ACTIVE INGREDIENT AS IMMEDIATE RELEASE | TORRENT PHARMACEUTICALS LTD (IN) | 2013-06-19 | — | — | EP | claimed |
| EP-1404309-B1 | A PHARMACEUTICAL COMBINATION COMPRISING EITHER (S)-2-ETHOXY-3- 4-(2- 4-METHANE SULFONYL OXYPHENYL ETHOXY) PHENYL| PROPANOIC ACID OR 3- 4- 2- (4-TERT-BUTOXY CARBONYL AMINOPHENYL) ETHOXY| PHENYL -(S)-2-ETHOXY PROPANOIC ACID AND A BIGUANIDE DRUG | ASTRAZENECA AB (SE) | 2006-08-23 | — | — | EP | claimed |
| EP-1666034-A1 | Pharmaceutical combination comprising a biguanide | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | claimed |
| WO-2005065639-A2 | NOVEL PHARMACEUTICAL COMPOSITIONS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2005-07-21 | — | — | WO | claimed |
| US-20040152771-A1 | Pharmaceutical combination comprising either (s)-2-ethoxy-3-[4-(2-{4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy car4bonyl aminophenyl) ethoxy] phenyl} -(s)-2-ethoxy propanoic acid and biguanide drug | ASTRAZENECA AB (SE) | 2004-08-05 | — | — | US | claimed |
| US-20040147600-A1 | Pharmaceutical combination comprising either (s)-2-ethoxy-3 [4-(2-{4-methane sulfonyl oxyphenyl} ethoxy)phenyl]propanoic acid or 3-{4-[2-(4-tert-butoxy carbonylamino phenyl)ethoxy]phenyl}-(s-2ethoxy propanoic acid and insulin | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | US | claimed |
| EP-1404309-A1 | A PHARMACEUTICAL COMBINATION COMPRISING EITHER (S)-2-ETHOXY-3- 4-(2- 4-METHANE SULFONYL OXYPHENYL ETHOXY) PHENYL] PROPANOIC ACID OR 3- 4- 2- (4-TERT-BUTOXY CARBONYL AMINOPHENYL) ETHOXY] PHENYL -(S)-2-ETHOXY PROPANOIC ACID AND A BIGUANIDE DRUG | AstraZeneca AB (SE) | 2004-04-07 | — | — | EP | claimed |
| EP-1401485-A1 | A PHARMACEUTICAL COMBINATION COMPRISING EITHER (S)-2-ETHOXY-3 4-(2- 4-METHANE SULFONYL OXYPHENYL ETHOXY)PHENYL] PROPANOIC ACID OR 3- 4- 2- (4-TERT-BUTOXY CARBONYLAMINO PHENYL) ETHOXY] PHENYL -(S)-2-ETHOXY PROPANOIC ACID AND INSULIN | AstraZeneca AB (SE) | 2004-03-31 | — | — | EP | claimed |
| EP-1399166-A1 | A PHARMACEUTICAL COMBINATION COMPRISING EITHER (S)-2-ETHOXY-3- 4-(2- 4-METHANE SULFONYL OXYPHENYL ETHOXY) PHENYL] PROPANOIC ACID OR 3- 4- 2-(4-TERT- BUTOXY CARBONYL AMINOPHENYL) ETHOXY] PHENYL -(s)-2-ETHOXY PROPANOIC ACID AND A SULONYLUREA | AstraZeneca AB (SE) | 2004-03-24 | — | — | EP | claimed |
| EP-1237855-B1 | CRYSTALLINE FORM OF (S)-2 ETHOXY-3- 4-(2- 4-METHANESULFONYLOXYPHENYL ETHOXY) PHENYL] PROPANOIC ACID | ASTRAZENECA AB (SE) | 2004-03-10 | — | — | EP | claimed |
| EP-1237854-B1 | COMMINUTED FORM OF (S)-2-ETHOXY -3- 4-(2- 4-METHANESULFONYLOXYPHENYL ETHOXY) PHENYL] PROPANOIC ACID | ASTRAZENECA AB (SE) | 2003-10-01 | — | — | EP | claimed |
| WO-2002100413-A1 | A PHARMACEUTICAL COMBINATION COMPRISING EITHER (S)-2-ETHOXY-3- [4-(2-{4-METHANE SULFONYL OXYPHENYL} ETHOXY) PHENYL] PROPANOIC ACID OR 3-{4-[2-(4-TERT- BUTOXY CARBONYL AMINOPHENYL) ETHOXY] PHENYL} -(s)-2-ETHOXY PROPANOIC ACID AND A SULONYLUREA | ASTRAZENECA AB (SE) | 2002-12-19 | — | — | WO | claimed |
| WO-2002096453-A1 | A PHARMACEUTICAL COMBINATION COMPRISING EITHER (S)-2-ETHOXY-3 [4-(2- {4-METHANE SULFONYL OXYPHENYL} ETHOXY)PHENYL] PROPANOIC ACID OR 3-{4-[2- (4-TERT-BUTOXY CARBONYLAMINO PHENYL) ETHOXY] PHENYL}-(S)-2-ETHOXY PROPANOIC ACID AND INSULIN | ASTRAZENECA AB (SE) | 2002-12-05 | — | — | WO | claimed |
| WO-2002096402-A1 | A PHARMACEUTICAL COMBINATION COMPRISING EITHER (S)-2-ETHOXY-3- [4-(2- {4-METHANE SULFONYL OXYPHENYL} ETHOXY) PHENYL] PROPANOIC ACID OR 3-{4-[2- (4-TERT-BUTOXY CARBONYL AMINOPHENYL) ETHOXY] PHENYL} -(S)-2-ETHOXY PROPANOIC ACID AND A BIGUANIDE DRUG | ASTRAZENECA AB (SE) | 2002-12-05 | — | — | WO | claimed |
| EP-1237854-A1 | COMMINUTED FORM OF (S)-2-ETHOXY -3- 4-(2- 4-METHANESULFONYLOXYPHENYL ETHOXY) PHENYL] PROPANOIC ACID | AstraZeneca AB (SE) | 2002-09-11 | — | — | EP | claimed |
| EP-1237855-A1 | CRYSTALLINE FORM OF (S)-2 ETHOXY-3- 4-(2- 4-METHANESULFONYLOXYPHENYL ETHOXY) PHENYL] PROPANOIC ACID | AstraZeneca AB (SE) | 2002-09-11 | — | — | EP | claimed |
| US-6258850-B1 | SULFONATE DERIVATIVES OF ETHER, ACIDS AS DRUGS | ASTRAZENECA AB (SE) | 2001-07-10 | — | — | US | claimed |
| WO-2001040169-A1 | COMMINUTED FORM OF (S)-2-ETHOXY -3-[4-(2- {4-METHANESULFONYLOXYPHENYL} ETHOXY) PHENYL] PROPANOIC ACID | ASTRAZENECA AB (SE) | 2001-06-07 | — | — | WO | claimed |
| WO-2001040171-A1 | CRYSTALLINE FORM OF (S)-2 ETHOXY-3-[4-(2-{4-METHANESULFONYLOXYPHENYL} ETHOXY) PHENYL] PROPANOIC ACID | ASTRAZENECA AB (SE) | 2001-06-07 | — | — | WO | claimed |
| US-20230330176-A1 | PHARMACEUTICAL COMBINATION COMPRISING AN IBAT INHIBITOR AND A BILE ACID BINDER | ALBIREO AB (SE) | 2023-10-19 | — | — | US | disclosed |
| US-11732006-B2 | IBAT inhibitors for the treatment of liver diseases | ALBIREO AB (SE) | 2023-08-22 | — | — | US | disclosed |
| US-20230109432-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | ALBIREO AB (SE) | 2023-04-06 | — | — | US | disclosed |
| US-11261212-B2 | IBAT inhibitors for the treatment of liver diseases | ALBIREO AB (SE) | 2022-03-01 | — | — | US | disclosed |
| US-20210340175-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | ALBIREO AB (SE) | 2021-11-04 | — | — | US | disclosed |
| US-10981952-B2 | IBAT inhibitors for the treatment of liver diseases | ALBIREO AB (SE) | 2021-04-20 | — | — | US | disclosed |
| EP-3777864-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | Albireo AB (SE) | 2021-02-17 | — | — | EP | disclosed |
| EP-3400944-B1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | ALBIREO AB (SE) | 2020-07-15 | — | — | EP | disclosed |
| US-20200140484-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | ALBIREO AB (SE) | 2020-05-07 | — | — | US | disclosed |
| US-10221212-B2 | IBAT inhibitors for the treatment of liver diseases | ALBIREO AB (SE) | 2019-03-05 | — | — | US | disclosed |
| US-20180362577-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | ALBIREO AB (SE) | 2018-12-20 | — | — | US | disclosed |
| EP-3400944-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | Albireo AB (SE) | 2018-11-14 | — | — | EP | disclosed |
| US-10093697-B2 | IBAT inhibitors for the treatment of liver diseases | ALBIREO AB | 2018-10-09 | — | — | US | disclosed |
| US-10011633-B2 | IBAT inhibitors for the treatment of liver diseases | ALBIREO AB (SE) | 2018-07-03 | — | — | US | disclosed |
| EP-3023102-B1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | ALBIREO AB (SE) | 2018-06-27 | — | — | EP | disclosed |
| US-10000528-B2 | IBAT inhibitors for the treatment of liver diseases | ALBIREO AB (SE) | 2018-06-19 | — | — | US | disclosed |
| US-20180162904-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | ALBIREO AB (SE) | 2018-06-14 | — | — | US | disclosed |
| US-20180030089-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | ALBIREO AB (SE) | 2018-02-01 | — | — | US | disclosed |
| US-20180030088-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | ALBIREO AB (SE) | 2018-02-01 | — | — | US | disclosed |
| US-20180022776-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | ALBIREO AB (SE) | 2018-01-25 | — | — | US | disclosed |
| EP-1427423-B9 | BENZOTHIAZEPINE AND BENZOTHIADIAZEPINE DERIVATIVES WITH ILEAL BILE ACID TRANSPORT (IBAT) INHIBITORY ACTIVITY FOR THE TREATMENT HYPERLIPIDAEMIA | ASTRAZENECA AB (SE) | 2017-12-20 | — | — | EP | disclosed |
| US-9694018-B1 | IBAT inhibitors for the treatment of liver disease | ALBIREO AB (SE) | 2017-07-04 | — | — | US | disclosed |
| US-20170182059-A1 | IBAT Inhibitors for the Treatment of Liver Disease | ALBIREO AB (SE) | 2017-06-29 | — | — | US | disclosed |
| US-20160194353-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | ALBIREO AB (SE) | 2016-07-07 | — | — | US | disclosed |
| EP-3023102-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | Albireo AB (SE) | 2016-05-25 | — | — | EP | disclosed |
| EP-2637646-B1 | A PHARMACEUTICAL COMBINATION COMPRISING AN IBAT INHIBITOR AND A BILE ACID BINDER | ALBIREO AB (SE) | 2016-05-11 | — | — | EP | disclosed |
| EP-2637668-B1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | ALBIREO AB (SE) | 2016-05-11 | — | — | EP | disclosed |
| EP-2637668-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | Albireo AB (SE) | 2013-09-18 | — | — | EP | disclosed |
| EP-2637646-A1 | A PHARMACEUTICAL COMBINATION COMPRISING AN IBAT INHIBITOR AND A BILE ACID BINDER | Albireo AB (SE) | 2013-09-18 | — | — | EP | disclosed |
| EP-2637667-A1 | IBAT INHIBITORS FOR TREATMENT OF METABOLIC DISORDERS AND RELATED CONDITIONS | Albireo AB (SE) | 2013-09-18 | — | — | EP | disclosed |
| EP-1708694-B1 | COMPOSITIONS AND METHODS FOR TREATING CONTRACTURE | ANGIOTECH INT AG (CH) | 2012-07-11 | — | — | EP | disclosed |
| WO-2012064268-A1 | IBAT INHIBITORS FOR TREATMENT OF METABOLIC DISORDERS AND RELATED CONDITIONS | ALBIREO AB (SE) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012064267-A1 | A PHARMACEUTICAL COMBINATION COMPRISING AN IBAT INHIBITOR AND A BILE ACID BINDER | ALBIREO AB (SE) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012064266-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | ALBIREO AB (SE) | 2012-05-18 | — | — | WO | disclosed |
| US-20120114588-A1 | IBAT INHIBITORS FOR TREATMENT OF METABOLIC DISORDERS AND RELATED CONDITIONS | ALBIREO AB (SE) | 2012-05-10 | — | — | US | disclosed |
| EP-1427713-B1 | BENZOTHIAZEPINE DERIVATIVES FOR THE TREATMENT OF HYPERLIPIDEMIA | ALBIREO AB (SE) | 2010-01-06 | — | — | EP | disclosed |
| US-20090214652-A1 | SOFT TISSUE IMPLANTS AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2009-08-27 | — | — | US | disclosed |
| EP-1430040-B1 | BENZOTHIAZEPINE DERIVATIVES | ALBIREO AB (SE) | 2009-08-05 | — | — | EP | disclosed |
| EP-1978930-A2 | SUTURES AND ANTI-SCARRING AGENTS | Angiotech Pharmaceuticals, Inc. (CA) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007089878-A2 | SUTURES AND ANTI-SCARRING AGENTS | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2007-08-09 | — | — | WO | disclosed |
| EP-1796602-A2 | MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE | Angiotech Pharmaceuticals (US), Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| EP-1345918-B1 | 1,5 BENZOTHIAZEPINES AND THEIR USE AS ANTIHYPERLIPIDEMICS | ASTRAZENECA AB (SE) | 2007-04-18 | — | — | EP | disclosed |
| US-7192945-B2 | Benzothiazepine derivatives | ASTRAZENECA AB (SE) | 2007-03-20 | — | — | US | disclosed |
| WO-2007004957-A1 | NOVEL CRYSTALLINE FORM | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | WO | disclosed |
| EP-1427423-B1 | BENZOTHIAZEPINE AND BENZOTHIADIAZEPINE DERIVATIVES WITH ILEAL BILE ACID TRANSPORT (IBAT) INHIBITORY ACTIVITY FOR THE TREATMENT HYPERLIPIDAEMIA | ASTRAZENECA AB (SE) | 2006-12-27 | — | — | EP | disclosed |
| US-20060282123-A1 | Electrical devices and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2006-12-14 | — | — | US | disclosed |
| EP-1427718-B1 | BENZOTHIEPINE ILEAL BILE ACID TRANSPORT INHIBOTORS | ASTRAZENECA AB (SE) | 2006-11-15 | — | — | EP | disclosed |
| EP-1708694-A2 | COMPOSITIONS AND METHODS FOR TREATING CONTRACTURE | ANGIOTECH INTERNATIONAL AG (CH) | 2006-10-11 | — | — | EP | disclosed |
| EP-1404309-B1 | A PHARMACEUTICAL COMBINATION COMPRISING EITHER (S)-2-ETHOXY-3- 4-(2- 4-METHANE SULFONYL OXYPHENYL ETHOXY) PHENYL| PROPANOIC ACID OR 3- 4- 2- (4-TERT-BUTOXY CARBONYL AMINOPHENYL) ETHOXY| PHENYL -(S)-2-ETHOXY PROPANOIC ACID AND A BIGUANIDE DRUG | ASTRAZENECA AB (SE) | 2006-08-23 | — | — | EP | disclosed |
| EP-1404309-B1 | A PHARMACEUTICAL COMBINATION COMPRISING EITHER (S)-2-ETHOXY-3- 4-(2- 4-METHANE SULFONYL OXYPHENYL ETHOXY) PHENYL| PROPANOIC ACID OR 3- 4- 2- (4-TERT-BUTOXY CARBONYL AMINOPHENYL) ETHOXY| PHENYL -(S)-2-ETHOXY PROPANOIC ACID AND A BIGUANIDE DRUG | ASTRAZENECA AB (SE) | 2006-08-23 | — | — | EP | disclosed |
| WO-2006083260-A2 | COMPOSITIONS AND SYSTEMS FOR FORMING CROSSLINKED BIOMATERIALS AND ASSOCIATED METHODS OF PREPARATION AND USE | ANGIOTECH BIOMATERIALS CORPORATION (US) | 2006-08-10 | — | — | WO | disclosed |
| EP-1687043-A2 | ELECTRICAL DEVICES AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2006-08-09 | — | — | EP | disclosed |
| EP-1687041-A2 | SOFT TISSUE IMPLANTS AND ANTI-SCARRING AGENTS | Angiotech International AG (CH) | 2006-08-09 | — | — | EP | disclosed |
| EP-1685085-A2 | IMPLANTABLE SENSORS AND IMPLANTABLE PUMPS AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2006-08-02 | — | — | EP | disclosed |
| EP-1684819-A2 | POLYMER COMPOSITIONS AND METHODS FOR THEIR USE | ANGIOTECH INTERNATIONAL AG (CH) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005051871-A9 | IMPLANTABLE SENSORS AND IMPLANTABLE PUMPS AND ANTI-SCARRING AGENTS | ANGIOTECH INT AG (CH) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006078282-A2 | COMPOSITIONS AND SYSTEMS FOR FORMING CROSSLINKED BIOMATERIALS AND ASSOCIATED METHODS OF PREPARATION AND USE | ANGIOTECH BIOMATERIALS CORPORATION (US) | 2006-07-27 | — | — | WO | disclosed |
| EP-1492764-B1 | PROCESS | ASTRAZENECA AB (SE) | 2006-06-28 | — | — | EP | disclosed |
| EP-1666034-A1 | Pharmaceutical combination comprising a biguanide | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | disclosed |
| EP-1666034-A1 | Pharmaceutical combination comprising a biguanide | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | disclosed |
| WO-2006055008-A2 | IMPLANTABLE SENSORS AND IMPLANTABLE PUMPS AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2006-05-26 | — | — | WO | disclosed |
| US-20060083790-A1 | Combination of an ibat inhibitor and a metal salt for the treatment of diarrhoea | ALBIREO AB (SE) | 2006-04-20 | — | — | US | disclosed |
| CN-1250226-C | Combination comprising -2-ethoxy-3- [4- (2- { 4-methanesulfonyloxyphenyl } ethoxy) phenyl ] propanoic acid or 3- {4- [2- (4-tert-butoxycarbonylaminophenyl) ethoxy ] phenyl } - -2-ethoxypropanoic acid and a sulfonylurea | ASTRAZENECA AB (SE) | 2006-04-12 | — | — | CN | disclosed |
| WO-2006034128-A2 | MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE | ANGIOTECH BIOMATERIALS CORPORATION (US) | 2006-03-30 | — | — | WO | disclosed |
| EP-1597245-A1 | BENZOTHIAZEPINE AND BENZOTHIEPINE DERIVATIVES | AstraZeneca AB (SE) | 2005-11-23 | — | — | EP | disclosed |
| US-20050215808-A1 | New process | ASTRAZENECA AB (SE) | 2005-09-29 | — | — | US | disclosed |
| US-20050208095-A1 | Polymer compositions and methods for their use | ANGIOTECH INTERNATIONAL AG (CH) | 2005-09-22 | — | — | US | disclosed |
| US-20050196421-A1 | Polymer compositions and methods for their use | ANGIOTECH INTERNATIONAL AG (CH) | 2005-09-08 | — | — | US | disclosed |
| CN-1216859-C | Comminuted form of (S)-2-ethoxy-3-[4-(2-{4-methane-sulfonyloxyphenyl} ethoxy) phenyl] propanoic acid | ASTRAZENECA AB (SE) | 2005-08-31 | — | — | CN | disclosed |
| US-20050186245-A1 | Implantable sensors and implantable pumps and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-25 | — | — | US | disclosed |
| US-20050183731-A1 | Polymer compositions and methods for their use | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-25 | — | — | US | disclosed |
| US-20050182463-A1 | Polymer compositions and methods for their use | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-18 | — | — | US | disclosed |
| US-20050182496-A1 | Soft tissue implants and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-18 | — | — | US | disclosed |
| WO-2005074913-A2 | COMPOSITIONS AND METHODS FOR TREATING CONTRACTURE | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-18 | — | — | WO | disclosed |
| US-20050181010-A1 | Implantable sensors and implantable pumps and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-18 | — | — | US | disclosed |
| US-20050181005-A1 | Implantable sensors and implantable pumps and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-18 | — | — | US | disclosed |
| US-20050181009-A1 | Implantable sensors and implantable pumps and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-18 | — | — | US | disclosed |
| US-20050169960-A1 | Implantable sensors and implantable pumps and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-04 | — | — | US | disclosed |
| US-20050169961-A1 | Implantable sensors and implantable pumps and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-04 | — | — | US | disclosed |
| US-20050158356-A1 | Implantable sensors and implantable pumps and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-07-21 | — | — | US | disclosed |
| US-20050154374-A1 | Implantable sensors and implantable pumps and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-07-14 | — | — | US | disclosed |
| US-20050152946-A1 | Implantable sensors and implantable pumps and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-07-14 | — | — | US | disclosed |
| EP-1539120-A1 | COMBINATION OF AN IBAT INHIBITOR AND A METAL SALT FOR THE TREATMENT OF DIARRHOEA | Astrazeneca AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| WO-2005051452-A2 | POLYMER COMPOSITIONS AND METHODS FOR THEIR USE | ANGIOTECH INTERNATIONAL AG (CH) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005051316-A2 | POLYMER COMPOSITIONS AND METHODS FOR THEIR USE | ANGIOTECH INTERNATIONAL AG (CH) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005051483-A2 | ELECTRICAL DEVICES AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005051444-A2 | SOFT TISSUE IMPLANTS AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005051871-A2 | IMPLANTABLE SENSORS AND IMPLANTABLE PUMPS AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005051232-A2 | SOFT TISSUE IMPLANTS AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005051451-A2 | ELECTRICAL DEVICES AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005046516-A2 | MEDICAL IMPLANTS AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2005-05-26 | — | — | WO | disclosed |
| CN-1198799-C | Crystalline form of (S)-2-ethoxy-3-[4-(2-{4-methane sulfonyloxy phenyl} ethoxy) phenyl] propanoic acid | ASTRAZENCA AB (SE) | 2005-04-27 | — | — | CN | disclosed |
| US-20050014955-A1 | Process for the preapartion 3-aryl-2-hydroxypropionic acid derivative | ASTRAZENECA AB (SE) | 2005-01-20 | — | — | US | disclosed |
| EP-1492764-A2 | NEW PROCESS | AstraZeneca AB (SE) | 2005-01-05 | — | — | EP | disclosed |
| CN-1537008-A | Combination comprising -2-ethoxy-3- [ 4- (2- { 4-methanesulfonyloxyphenyl } ethoxy) phenyl ] propanoic acid or 3- { 4- [ 2- (4-tert-butoxycarbonylaminophenyl) ethoxy ] phenyl } - -2-ethoxypropanoic acid and a sulfonylurea | — | 2004-10-13 | — | — | CN | disclosed |
| CN-1535144-A | Pharmaceutical combination comprising either (S)-2-ethoxy-3-[4-(2-{4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic aicd or 3-{4-[2-(4-tert-butoxy carbonyl aminophenyl) ethyoxy] phenyl} | — | 2004-10-06 | — | — | CN | disclosed |
| CN-1535155-A | A combination comprising -2-ethoxy-3- [ 4- (2- { 4-methanesulfonyloxyphenyl } ethoxy) phenyl ] propanoic acid or 3- { 4- [ 2- (4-tert-butoxycarbonylaminophenyl) ethoxy ] phenyl } - -2-ethoxypropanoic acid and insulin | — | 2004-10-06 | — | — | CN | disclosed |
| WO-2004076430-A1 | BENZOTHIAZEPINE AND BENZOTHIEPINE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-09-10 | — | — | WO | disclosed |
| US-20040152771-A1 | Pharmaceutical combination comprising either (s)-2-ethoxy-3-[4-(2-{4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy car4bonyl aminophenyl) ethoxy] phenyl} -(s)-2-ethoxy propanoic acid and biguanide drug | ASTRAZENECA AB (SE) | 2004-08-05 | — | — | US | disclosed |
| US-20040152771-A1 | Pharmaceutical combination comprising either (s)-2-ethoxy-3-[4-(2-{4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy car4bonyl aminophenyl) ethoxy] phenyl} -(s)-2-ethoxy propanoic acid and biguanide drug | ASTRAZENECA AB (SE) | 2004-08-05 | — | — | US | disclosed |
| US-20040147600-A1 | Pharmaceutical combination comprising either (s)-2-ethoxy-3 [4-(2-{4-methane sulfonyl oxyphenyl} ethoxy)phenyl]propanoic acid or 3-{4-[2-(4-tert-butoxy carbonylamino phenyl)ethoxy]phenyl}-(s-2ethoxy propanoic acid and insulin | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | US | disclosed |
| US-20040147600-A1 | Pharmaceutical combination comprising either (s)-2-ethoxy-3 [4-(2-{4-methane sulfonyl oxyphenyl} ethoxy)phenyl]propanoic acid or 3-{4-[2-(4-tert-butoxy carbonylamino phenyl)ethoxy]phenyl}-(s-2ethoxy propanoic acid and insulin | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | US | disclosed |
| EP-1430040-A1 | BENZOTHIAZEPINE DERIVATIVES | Astrazeneca AB (SE) | 2004-06-23 | — | — | EP | disclosed |
| EP-1427713-A1 | BENZOTHIAZEPINE DERIVATIVES FOR THE TREATMENT OF HYPERLIPIDEMIA | Astrazeneca AB (SE) | 2004-06-16 | — | — | EP | disclosed |
| EP-1427423-A1 | BENZOTHIAZEPINE AND BENZOTHIADIAZEPINE DERIVATIVES WITH ILEAL BILE ACID TRANSPORT (IBAT) INHIBITORY ACTIVITY FOR THE TREATMENT HYPERLIPIDAEMIA | AstraZeneca AB (SE) | 2004-06-16 | — | — | EP | disclosed |
| EP-1427718-A1 | BENZOTHIEPINE ILEAL BILE ACID TRANSPORT INHIBOTORS | AstraZeneca AB (SE) | 2004-06-16 | — | — | EP | disclosed |
| US-20040067933-A1 | Chemical compounds | ELOBIX AB (SE) | 2004-04-08 | — | — | US | disclosed |
| EP-1404651-A1 | PROCESS FOR THE PREPARATION 3-ARYL-2-HYDROXYPROPIONIC ACID DERIVATIVE | AstraZeneca AB (SE) | 2004-04-07 | — | — | EP | disclosed |
| EP-1404309-A1 | A PHARMACEUTICAL COMBINATION COMPRISING EITHER (S)-2-ETHOXY-3- 4-(2- 4-METHANE SULFONYL OXYPHENYL ETHOXY) PHENYL] PROPANOIC ACID OR 3- 4- 2- (4-TERT-BUTOXY CARBONYL AMINOPHENYL) ETHOXY] PHENYL -(S)-2-ETHOXY PROPANOIC ACID AND A BIGUANIDE DRUG | AstraZeneca AB (SE) | 2004-04-07 | — | — | EP | disclosed |
| EP-1404309-A1 | A PHARMACEUTICAL COMBINATION COMPRISING EITHER (S)-2-ETHOXY-3- 4-(2- 4-METHANE SULFONYL OXYPHENYL ETHOXY) PHENYL] PROPANOIC ACID OR 3- 4- 2- (4-TERT-BUTOXY CARBONYL AMINOPHENYL) ETHOXY] PHENYL -(S)-2-ETHOXY PROPANOIC ACID AND A BIGUANIDE DRUG | AstraZeneca AB (SE) | 2004-04-07 | — | — | EP | disclosed |
| EP-1401485-A1 | A PHARMACEUTICAL COMBINATION COMPRISING EITHER (S)-2-ETHOXY-3 4-(2- 4-METHANE SULFONYL OXYPHENYL ETHOXY)PHENYL] PROPANOIC ACID OR 3- 4- 2- (4-TERT-BUTOXY CARBONYLAMINO PHENYL) ETHOXY] PHENYL -(S)-2-ETHOXY PROPANOIC ACID AND INSULIN | AstraZeneca AB (SE) | 2004-03-31 | — | — | EP | disclosed |
| EP-1401485-A1 | A PHARMACEUTICAL COMBINATION COMPRISING EITHER (S)-2-ETHOXY-3 4-(2- 4-METHANE SULFONYL OXYPHENYL ETHOXY)PHENYL] PROPANOIC ACID OR 3- 4- 2- (4-TERT-BUTOXY CARBONYLAMINO PHENYL) ETHOXY] PHENYL -(S)-2-ETHOXY PROPANOIC ACID AND INSULIN | AstraZeneca AB (SE) | 2004-03-31 | — | — | EP | disclosed |
| EP-1399166-A1 | A PHARMACEUTICAL COMBINATION COMPRISING EITHER (S)-2-ETHOXY-3- 4-(2- 4-METHANE SULFONYL OXYPHENYL ETHOXY) PHENYL] PROPANOIC ACID OR 3- 4- 2-(4-TERT- BUTOXY CARBONYL AMINOPHENYL) ETHOXY] PHENYL -(s)-2-ETHOXY PROPANOIC ACID AND A SULONYLUREA | AstraZeneca AB (SE) | 2004-03-24 | — | — | EP | disclosed |
| EP-1399166-A1 | A PHARMACEUTICAL COMBINATION COMPRISING EITHER (S)-2-ETHOXY-3- 4-(2- 4-METHANE SULFONYL OXYPHENYL ETHOXY) PHENYL] PROPANOIC ACID OR 3- 4- 2-(4-TERT- BUTOXY CARBONYL AMINOPHENYL) ETHOXY] PHENYL -(s)-2-ETHOXY PROPANOIC ACID AND A SULONYLUREA | AstraZeneca AB (SE) | 2004-03-24 | — | — | EP | disclosed |
| EP-1237855-B1 | CRYSTALLINE FORM OF (S)-2 ETHOXY-3- 4-(2- 4-METHANESULFONYLOXYPHENYL ETHOXY) PHENYL] PROPANOIC ACID | ASTRAZENECA AB (SE) | 2004-03-10 | — | — | EP | disclosed |
| EP-1237855-B1 | CRYSTALLINE FORM OF (S)-2 ETHOXY-3- 4-(2- 4-METHANESULFONYLOXYPHENYL ETHOXY) PHENYL] PROPANOIC ACID | ASTRAZENECA AB (SE) | 2004-03-10 | — | — | EP | disclosed |
| WO-2004006899-A1 | COMBINATION OF AN IBAT INHIBITOR AND A METAL SALT FOR THE TREATMENT OF DIARRHOEA | ASTRAZENECA AB (SE) | 2004-01-22 | — | — | WO | disclosed |
| WO-2003082812-A2 | PROCESS FOR THE PREPARATION OF 2-ETHOXY-3-[4-(2-{METHANESULPHONYLOXYPHENYL}ETHOXY) PHENIL] PROPANOIC ACID | ASTRAZENECA AB (SE) | 2003-10-09 | — | — | WO | disclosed |
| EP-1237854-B1 | COMMINUTED FORM OF (S)-2-ETHOXY -3- 4-(2- 4-METHANESULFONYLOXYPHENYL ETHOXY) PHENYL] PROPANOIC ACID | ASTRAZENECA AB (SE) | 2003-10-01 | — | — | EP | disclosed |
| EP-1237854-B1 | COMMINUTED FORM OF (S)-2-ETHOXY -3- 4-(2- 4-METHANESULFONYLOXYPHENYL ETHOXY) PHENYL] PROPANOIC ACID | ASTRAZENECA AB (SE) | 2003-10-01 | — | — | EP | disclosed |
| EP-1345918-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2003-09-24 | — | — | EP | disclosed |
| CN-1409701-A | Crystalline forms of -2-ethoxy-3- [ 4- (2- { 4-methanesulfonyloxyphenyl } ethoxy) phenyl ] propanoic acid | ASTRAZENCA AB (SE) | 2003-04-09 | — | — | CN | disclosed |
| WO-2003022825-A1 | BENZOTHIAZEPINE DERIVATIVES FOR THE TREATMENT OF HYPERLIPIDEMIA | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | WO | disclosed |
| WO-2003022286-A1 | BENZOTHIAZEPINE AND BENZOTHIADIAZEPINE DERIVATIVES WITH ILEAL BILE ACID TRANSPORT (IBAT) INHIBITORY ACTIVITY FOR THE TREATMENT HYPERLIPIDAEMIA | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | WO | disclosed |
| WO-2003022830-A1 | BENZOTHIEPINE ILEAL BILE ACID TRANSPORT INHIBITORS | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | WO | disclosed |
| WO-2003020710-A1 | BENZOTHIAZEPINE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-03-13 | — | — | WO | disclosed |
| CN-1402704-A | Comminuted form of (S) -2-ethoxy-3- [ 4- (2- { 4-methanesulfonyloxyphenyl } ethoxy) phenyl ] propanoic acid | ASTRAZENECA AB (SE) | 2003-03-12 | — | — | CN | disclosed |
| US-6531622-B1 | Insulin Resistance Syndrome; metabolic disorders; crystallization | ASTRAZENECA AB (SE) | 2003-03-11 | — | — | US | disclosed |
| WO-2002100413-A1 | A PHARMACEUTICAL COMBINATION COMPRISING EITHER (S)-2-ETHOXY-3- [4-(2-{4-METHANE SULFONYL OXYPHENYL} ETHOXY) PHENYL] PROPANOIC ACID OR 3-{4-[2-(4-TERT- BUTOXY CARBONYL AMINOPHENYL) ETHOXY] PHENYL} -(s)-2-ETHOXY PROPANOIC ACID AND A SULONYLUREA | ASTRAZENECA AB (SE) | 2002-12-19 | — | — | WO | disclosed |
| WO-2002100413-A1 | A PHARMACEUTICAL COMBINATION COMPRISING EITHER (S)-2-ETHOXY-3- [4-(2-{4-METHANE SULFONYL OXYPHENYL} ETHOXY) PHENYL] PROPANOIC ACID OR 3-{4-[2-(4-TERT- BUTOXY CARBONYL AMINOPHENYL) ETHOXY] PHENYL} -(s)-2-ETHOXY PROPANOIC ACID AND A SULONYLUREA | ASTRAZENECA AB (SE) | 2002-12-19 | — | — | WO | disclosed |
| WO-2002096453-A1 | A PHARMACEUTICAL COMBINATION COMPRISING EITHER (S)-2-ETHOXY-3 [4-(2- {4-METHANE SULFONYL OXYPHENYL} ETHOXY)PHENYL] PROPANOIC ACID OR 3-{4-[2- (4-TERT-BUTOXY CARBONYLAMINO PHENYL) ETHOXY] PHENYL}-(S)-2-ETHOXY PROPANOIC ACID AND INSULIN | ASTRAZENECA AB (SE) | 2002-12-05 | — | — | WO | disclosed |
| WO-2002096453-A1 | A PHARMACEUTICAL COMBINATION COMPRISING EITHER (S)-2-ETHOXY-3 [4-(2- {4-METHANE SULFONYL OXYPHENYL} ETHOXY)PHENYL] PROPANOIC ACID OR 3-{4-[2- (4-TERT-BUTOXY CARBONYLAMINO PHENYL) ETHOXY] PHENYL}-(S)-2-ETHOXY PROPANOIC ACID AND INSULIN | ASTRAZENECA AB (SE) | 2002-12-05 | — | — | WO | disclosed |
| WO-2002096865-A1 | PROCESS FOR THE PREPARATION 3-ARYL-2-HYDROXYPROPIONIC ACID DERIVATIVE | ASTRAZENECA AB (SE) | 2002-12-05 | — | — | WO | disclosed |
| WO-2002096402-A1 | A PHARMACEUTICAL COMBINATION COMPRISING EITHER (S)-2-ETHOXY-3- [4-(2- {4-METHANE SULFONYL OXYPHENYL} ETHOXY) PHENYL] PROPANOIC ACID OR 3-{4-[2- (4-TERT-BUTOXY CARBONYL AMINOPHENYL) ETHOXY] PHENYL} -(S)-2-ETHOXY PROPANOIC ACID AND A BIGUANIDE DRUG | ASTRAZENECA AB (SE) | 2002-12-05 | — | — | WO | disclosed |
| WO-2002096402-A1 | A PHARMACEUTICAL COMBINATION COMPRISING EITHER (S)-2-ETHOXY-3- [4-(2- {4-METHANE SULFONYL OXYPHENYL} ETHOXY) PHENYL] PROPANOIC ACID OR 3-{4-[2- (4-TERT-BUTOXY CARBONYL AMINOPHENYL) ETHOXY] PHENYL} -(S)-2-ETHOXY PROPANOIC ACID AND A BIGUANIDE DRUG | ASTRAZENECA AB (SE) | 2002-12-05 | — | — | WO | disclosed |
| EP-1237854-A1 | COMMINUTED FORM OF (S)-2-ETHOXY -3- 4-(2- 4-METHANESULFONYLOXYPHENYL ETHOXY) PHENYL] PROPANOIC ACID | AstraZeneca AB (SE) | 2002-09-11 | — | — | EP | disclosed |
| EP-1237855-A1 | CRYSTALLINE FORM OF (S)-2 ETHOXY-3- 4-(2- 4-METHANESULFONYLOXYPHENYL ETHOXY) PHENYL] PROPANOIC ACID | AstraZeneca AB (SE) | 2002-09-11 | — | — | EP | disclosed |
| EP-1237855-A1 | CRYSTALLINE FORM OF (S)-2 ETHOXY-3- 4-(2- 4-METHANESULFONYLOXYPHENYL ETHOXY) PHENYL] PROPANOIC ACID | AstraZeneca AB (SE) | 2002-09-11 | — | — | EP | disclosed |
| EP-1237854-A1 | COMMINUTED FORM OF (S)-2-ETHOXY -3- 4-(2- 4-METHANESULFONYLOXYPHENYL ETHOXY) PHENYL] PROPANOIC ACID | AstraZeneca AB (SE) | 2002-09-11 | — | — | EP | disclosed |
| WO-2002050051-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2002-06-27 | — | — | WO | disclosed |
| WO-2001040171-A1 | CRYSTALLINE FORM OF (S)-2 ETHOXY-3-[4-(2-{4-METHANESULFONYLOXYPHENYL} ETHOXY) PHENYL] PROPANOIC ACID | ASTRAZENECA AB (SE) | 2001-06-07 | — | — | WO | disclosed |
| WO-2001040171-A1 | CRYSTALLINE FORM OF (S)-2 ETHOXY-3-[4-(2-{4-METHANESULFONYLOXYPHENYL} ETHOXY) PHENYL] PROPANOIC ACID | ASTRAZENECA AB (SE) | 2001-06-07 | — | — | WO | disclosed |
| WO-2001040171-A1 | CRYSTALLINE FORM OF (S)-2 ETHOXY-3-[4-(2-{4-METHANESULFONYLOXYPHENYL} ETHOXY) PHENYL] PROPANOIC ACID | ASTRAZENECA AB (SE) | 2001-06-07 | — | — | WO | disclosed |
| WO-2001040169-A1 | COMMINUTED FORM OF (S)-2-ETHOXY -3-[4-(2- {4-METHANESULFONYLOXYPHENYL} ETHOXY) PHENYL] PROPANOIC ACID | ASTRAZENECA AB (SE) | 2001-06-07 | — | — | WO | disclosed |
| WO-2001040169-A1 | COMMINUTED FORM OF (S)-2-ETHOXY -3-[4-(2- {4-METHANESULFONYLOXYPHENYL} ETHOXY) PHENYL] PROPANOIC ACID | ASTRAZENECA AB (SE) | 2001-06-07 | — | — | WO | disclosed |
| WO-2001040169-A1 | COMMINUTED FORM OF (S)-2-ETHOXY -3-[4-(2- {4-METHANESULFONYLOXYPHENYL} ETHOXY) PHENYL] PROPANOIC ACID | ASTRAZENECA AB (SE) | 2001-06-07 | — | — | WO | disclosed |
| WO-2001040171-A1 | CRYSTALLINE FORM OF (S)-2 ETHOXY-3-[4-(2-{4-METHANESULFONYLOXYPHENYL} ETHOXY) PHENYL] PROPANOIC ACID | ASTRAZENECA AB (SE) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (28 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114588-A1 | IBAT INHIBITORS FOR TREATMENT OF METABOLIC DISORDERS AND RELATED CONDITIONS | GPR119, SLC5A1, GABRQ | PPARA 295/4885PPARG 95/4885PPARD 302/4885 |
| US-20230109432-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | GPR119, SLC10A1, SLC10A2 | PPARA 373/4885PPARG 125/4885PPARD 488/4885 |
| US-11732006-B2 | IBAT inhibitors for the treatment of liver diseases | GPR119, SLC10A1, SLC10A2 | PPARA 373/4885PPARG 125/4885PPARD 488/4885 |
| US-10221212-B2 | IBAT inhibitors for the treatment of liver diseases | GPR119, SLC10A1, SLC10A2 | PPARA 373/4885PPARG 125/4885PPARD 488/4885 |
| US-20050152946-A1 | Implantable sensors and implantable pumps and anti-scarring agents | MMP1, CDKN1A, MKI67 | PPARA 2202/4885PPARG 2526/4885PPARD 3358/4885 |
| US-20160194353-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | GPR119, SLC10A1, SLC10A2 | PPARA 373/4885PPARG 125/4885PPARD 488/4885 |
| US-20040067933-A1 | Chemical compounds | SLC10A2, SLC10A1, ABCB11 | PPARA 644/4885PPARG 418/4885PPARD 654/4885 |
| US-20180030088-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | GPR119, SLC10A1, SLC10A2 | PPARA 373/4885PPARG 125/4885PPARD 488/4885 |
| US-20180022776-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | GPR119, SLC10A1, SLC10A2 | PPARA 373/4885PPARG 125/4885PPARD 488/4885 |
| US-20170182059-A1 | IBAT Inhibitors for the Treatment of Liver Disease | SLC10A2, SLC10A1, GPR119 | PPARA 423/4885PPARG 149/4885PPARD 462/4885 |
| US-20050186245-A1 | Implantable sensors and implantable pumps and anti-scarring agents | MMP1, CDKN1A, MKI67 | PPARA 2202/4885PPARG 2526/4885PPARD 3358/4885 |
| US-20050169961-A1 | Implantable sensors and implantable pumps and anti-scarring agents | MMP1, CDKN1A, MKI67 | PPARA 2202/4885PPARG 2526/4885PPARD 3358/4885 |
| US-10093697-B2 | IBAT inhibitors for the treatment of liver diseases | GPR119, SLC10A1, SLC10A2 | PPARA 373/4885PPARG 125/4885PPARD 488/4885 |
| US-10011633-B2 | IBAT inhibitors for the treatment of liver diseases | GPR119, SLC10A1, SLC10A2 | PPARA 373/4885PPARG 125/4885PPARD 488/4885 |
| US-20200140484-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | GPR119, SLC10A1, SLC10A2 | PPARA 373/4885PPARG 125/4885PPARD 488/4885 |
| US-10000528-B2 | IBAT inhibitors for the treatment of liver diseases | GPR119, SLC10A1, SLC10A2 | PPARA 373/4885PPARG 125/4885PPARD 488/4885 |
| US-20060083790-A1 | Combination of an ibat inhibitor and a metal salt for the treatment of diarrhoea | SLC10A2, SI, SLC6A1 | PPARA 2321/4885PPARG 1297/4885PPARD 2215/4885 |
| US-20090214652-A1 | SOFT TISSUE IMPLANTS AND ANTI-SCARRING AGENTS | MMP1, COL2A1, FN1 | PPARA 361/4885PPARG 1038/4885PPARD 1476/4885 |
| US-20180362577-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | GPR119, SLC10A1, SLC10A2 | PPARA 373/4885PPARG 125/4885PPARD 488/4885 |
| US-10981952-B2 | IBAT inhibitors for the treatment of liver diseases | GPR119, SLC10A1, SLC10A2 | PPARA 373/4885PPARG 125/4885PPARD 488/4885 |
| US-20050014955-A1 | Process for the preapartion 3-aryl-2-hydroxypropionic acid derivative | GRHPR, PAH, P4HA1 | PPARA 2485/4885PPARG 2770/4885PPARD 3461/4885 |
| US-20050154374-A1 | Implantable sensors and implantable pumps and anti-scarring agents | MMP1, CDKN1A, MKI67 | PPARA 2202/4885PPARG 2526/4885PPARD 3358/4885 |
| US-11261212-B2 | IBAT inhibitors for the treatment of liver diseases | GPR119, SLC10A1, SLC10A2 | PPARA 373/4885PPARG 125/4885PPARD 488/4885 |
| US-20210340175-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | GPR119, SLC10A1, SLC10A2 | PPARA 373/4885PPARG 125/4885PPARD 488/4885 |
| US-20180162904-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | GPR119, SLC10A1, SLC10A2 | PPARA 373/4885PPARG 125/4885PPARD 488/4885 |
| US-20230330176-A1 | PHARMACEUTICAL COMBINATION COMPRISING AN IBAT INHIBITOR AND A BILE ACID BINDER | SLC10A2, SLC10A1, GPBAR1 | PPARA 570/4885PPARG 341/4885PPARD 831/4885 |
| US-20050215808-A1 | New process | CFH, REN, CYP11B2 | PPARA 4075/4885PPARG 3890/4885PPARD 4224/4885 |
| US-20180030089-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | GPR119, SLC10A1, SLC10A2 | PPARA 373/4885PPARG 125/4885PPARD 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.